Mersana Therapeutics, Inc. (MRSN) Covered Calls

You can sell covered calls on Mersana Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MRSN (prices last updated Fri 4:16 PM ET):

Mersana Therapeutics, Inc. (MRSN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.21 -0.31 2.21 2.33 1.0M - 0.3
Covered Calls For Mersana Therapeutics, Inc. (MRSN)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Dec 20 2 0.00 2.33 -14.2% -144.0%
Jan 17 2 0.45 1.88 6.4% 36.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.